Seer Files Preliminary Proxy Statement Amidst Proxy Fight, Urges Vote Against Activist Nominees and for Poison Pill Ratification

summarizeSummary

Seer has filed its preliminary proxy statement, formally initiating a proxy contest against an activist investor group. The company is defending its board and urging shareholders to ratify its poison pill, while rejecting the activist's acquisition offers.

check_boxKey Events

• Proxy Contest Underway

  The company is engaged in a proxy fight with the Radoff-JEC Group, which holds a 7.8% stake and has nominated three directors for election at the upcoming annual meeting.

• Acquisition Offer Rejected

  The Board unanimously rejected the activist's latest unsolicited offer of $2.40 per share, stating it "significantly undervalues Seer," despite the company's recent 34% revenue decline and increased cash burn. The offer represents a substantial premium to the current stock price of $1.69.

• Poison Pill Ratification Sought

  Shareholders will vote on ratifying the Tax Benefit Preservation Plan, a poison pill adopted in February 2026 to protect $282.5 million in net operating losses (NOLs) and deter acquisitions of 4.9% or more. If not ratified, the plan expires in February 2027.

• Board Recommends Against Activist Nominees

  The Board is actively soliciting votes for its seven director nominees and against the activist's candidates, urging shareholders to use the company's 'BLUE' proxy card.

auto_awesomeAnalysis

This preliminary proxy statement details Seer's defense against an activist investor group, the Radoff-JEC Group, which is seeking board seats and has made multiple unsolicited acquisition proposals. The Board is urging shareholders to vote for its director nominees and to ratify the Tax Benefit Preservation Plan (poison pill), which is designed to protect the company's substantial net operating losses (NOLs) and deter hostile takeovers. The activist group's latest offer of $2.40 per share represents a significant premium to the current stock price, but the Board has rejected it, citing undervaluation. The upcoming annual meeting will be a critical vote on the company's future direction and control.